Headache News

The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in adults, according to the manufacturer.

SAN DIEGO —American Indians are less likely to receive a migraine diagnosis or migraine treatment compared with their white counterparts due to a variety of socioeconomic factors, according to a poster.

SAN DIEGO — Children and adolescents treated with fremanezumab experienced fewer migraine and headache days compared with placebo, according to an abstract presented at the American Academy of Neurology Annual Meeting.

SAN DIEGO — Over-the-counter pain relievers improved concussion symptoms and time to recovery, with earlier use providing the greatest benefit, according to a speaker.

SAN DIEGO — Significantly more patients with acute migraine who received a 10 L per minute dose of a transnasal cooling device had pain freedom at 2 hours vs. those who received sham, according to research presented at the AAN Annual Meeting.

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly migraine days, particularly after at least 2 months of use, preliminary data show.

The International Headache Society recently issued a position paper that upgraded the standards for migraine prevention, providing a four-pronged framework for reassessing the goals for migraine control and prevention.

ACP released new clinical guidance on outpatient treatment of acute episodic migraine with combination therapy in patients who are not pregnant or lactating in outpatient settings.

WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.